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Background and purpose: Previous studies confirmed that implantable rectum spacers (IRS) decreased
acute gastro-intestinal (GI) toxicity in a significant percentage of prostate cancer patients undergoing
intensity modulated radiation therapy (IMRT). We developed decision rules based on clinical risk factors
(CRFs) to select those patients who are expected to benefit most from IRS implantation.
Materials and methods: For 26 patients dose distributions with (IMRT + IRS) and without (IMRT  IRS) IRS
were calculated. Validated nomograms based on CRFs and dosimetric criteria (anorectal V40Gy and V75Gy)
were used to predict probabilities for grade 2–3 (G2–3) acute GI toxicity, G2–3 late rectal bleeding (LRB),
G3 LRB, and G2–3 faecal incontinence (FI) for IMRT + IRS and IMRT  IRS. All permutations of CRFs were
generated to identify most benefit scenarios (MBS) in which a predicted toxicity reduction ofP5% points
in P25% of the cohort was present due to IRS implantation.
Results: IMRT + IRS revealed a significant reduction in V40Gy (p = 0.0357) and V75Gy (p < 0.0001) relative to
IMRT  IRS. For G2-3 acute GI toxicity and G2–3 LRB, the predicted toxicity rates decreased in 17/26
(65%) and 20/26 (77%) patients, and decision rules were derived for 22/32 (69%) and 12/64 (19%) MBS,
respectively. From the decision rules, it follows that diabetes status has no impact on G2–3 acute toxicity,
and in absence of pre-RT abdominal surgery, the implantation of an IRS is predicted to show no clinically
relevant benefit for G2–3 LRB.
Conclusions: Prostate cancer patients who are expected to benefit most from IRS implantation can be
identified prior to IMRT based on their CRFs profile.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 121 (2016) 118–123
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Despite recent improvements, image-guided radiotherapy and
highly-conformal dose delivery techniques for prostate cancer
are still associated with severe gastro-intestinal (GI) toxicity. As a
result, a significant percentage of patients suffer from a negative
impact on their quality of life [1–3]. Various temporary or long-
term implantable medical devices have been developed to spare
rectal structures by excluding them from high-dose radiation
exposure. Endo-rectal balloons are used to increase the distance
from the dorsal rectal wall to the prostate [4]. Implanted rectum
spacers (IRS) are used to separate the anterior rectal wall fromthe prostate by injecting an absorbable hydrogel or hyaluronic
acid, or by placing a saline-filled balloon or collagen implant [5–8].
Several studies have confirmed that an IRS decreases the rectal
dose and consequently also the acute rectal toxicity to such an
extent that the costs of IRS placement are justified [5–14]. A better
selection of patients with a decision support system to implant an
IRS would further enhance cost-effectiveness, an issue that is
becoming increasingly important due to ever-expanding expenses
in health care [14,15]. Since the follow-up interval of the studies
conducted is still too short, no long-term late toxicity scores have
been reported yet. Instead, validated multifactorial nomograms
based on clinical risk factors and dosimetric data can be exploited
to predict toxicity scores [16,17].
In the current study, we used such nomograms to test the
hypothesis that implanting a hydrogel IRS in patients with prostate
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(IMRT + IRS) reduces the predicted grade 2–3 (G2–3) acute and late
rectal toxicities in comparison to patients undergoing IMRT
without IRS (IMRT  IRS). Furthermore, we identified scenarios of
clinical risk factors for which implantation of an IRS is predicted
to significantly reduce G2–3 acute and late rectal toxicity rates in
a sufficiently large proportion of patients. Finally, we generate
decision rules for the toxicity end-points covering these sets of
scenarios, making it possible to select those patients who are
expected to benefit most from an IRS implantation prior to
treatment planning for IMRT.Materials and methods
Patient characteristics
This study included 26 patients with localized prostate cancer
who had signed an informed consent form, after approval by the
ethics committee of the University Hospital RWTH Aachen, where
these patients were treated. Patients for this study were consecu-
tively selected in 2011 [5,18]. The patient and tumour characteris-
tics are summarized in Table 1. Prognostic risk-group stratification
of the patients was defined according to the D’Amico classification
[19].Table 1
Patient (N = 26) and tumour characteristics.
Age (years; median [range]) 73 [56–82]
Prognostic risk groupa: (No. of patients)
1. Low-risk 8 (31%)
2. Intermediate-risk 11 (42%)
3. High-risk 7 (27%)
Prostate volume: (cm3; median [range])
PTV 50 [25–130]
Clinical risk factors for nomograms: (No. of patients)
Diabetes 4
Haemorrhoids 2
Previous abdominal surgery 2
Anticoagulant drugs 7
Hormonal therapy 7
Anti-hypertensives 11
Abbreviation: PTV = planning target volume.
a Low-risk: no risk factors: PSA < 10 ng/ml; Gleason score < 7; cT-stage < 2b;
Intermediate-risk: one risk factor: PSA 10–20 ng/ml or Gleason score = 7 or
cT-stage = 2b/c; High-risk: two risk factors or PSA > 20 ng/ml or Gleason score > 7 or
cT-stage > 2b/c.
Fig. 1. Color-wash dose distribution in an axial plane before (a) and after (b) IRS gel inject
dose region > 75% (red) overlaps with the anterior part of the rectum (brown), while with
isodose contour (purple) overlaps the entire rectum in (a), whereas it overlaps the rectuRectum spacer implantation
In these patients, a 10 cm3 IRS gel (SpaceOARTM System, Aug-
menix Inc., Waltham, MA) was injected in the recto-prostatic space
prior to IMRT planning and dose delivery. This IRS implantation
technique has been described previously by Pinkawa et al. [5].Image acquisition and organ delineation
Every patient underwent two computed tomography (CT) scans
in supine position with a slice thickness of 5 mm: one CT scan prior
to IRS implantation and one 3–5 days after IRS implantation. In
total, 52 CT scans were imported into the Pinnacle3 radiation treat-
ment planning system (Version 8.0 m, Philips Medical Systems,
Fitchburg, WI) to calculate clinically acceptable dose distributions
for IMRT  IRS and IMRT + IRS (Fig. 1). For accurate target volume
delineation, T2-weighted magnetic resonance imaging (MRI) scans
were additionally performed after IRS implantation. After registra-
tion with the corresponding CT scans the prostate, the adjacent
rectal wall, and the IRS gel (for volumetric analysis) were
contoured.
Depending on the prognostic risk group, the clinical target vol-
ume (CTV) was defined as the prostate only (CTV1), the prostate
including the proximal 2–4 slices of the seminal vesicles depicted
on CT (CTV2), or the prostate with the entire seminal vesicles
(CTV3) [20]. To generate the planning target volume (PTV), the
CTV was expanded by 8 mm in lateral–anterior, 5 mm in supe-
rior–inferior and 4 mm in posterior direction, as described in an
earlier study [5,12]. Moreover, the bladder, femoral heads, anus,
rectum and the outer anorectal wall contour (anal canal up to
the recto-sigmoid flexure) were contoured as organs at risk on
the CT scans. To allow for intercomparison between IMRT  IRS
and IMRT + IRS planned dose distributions, the delineated cranio-
caudal distance was chosen to be identical for each patient and
for every pre- and post- IRS-implant CT scan, resulting in the same
anal and rectal length per patient. Two independent observers (MP
and BV) performed the delineations.Treatment planning technique
All IMRT  IRS and IMRT + IRS treatment plans were designed
by inverse planning using a direct machine parameter optimiza-
tion (DMPO) algorithm for step-and-shoot IMRT with 5 coplanar
15 MV photon beams (gantry angles: 45, 105, 180, 255, 315)ion in the same patient, with prostate (yellow) and PTV (red). Without IRS, the high-
IRS in situ the high-dose region spans the IRS (black), and not the rectum. The 40%
m partially in (b). Abbreviation: IRS = implantable rectum spacer.
120 Patient selection for spacer implantation[21]. The dose grid included the PTV, organs at risk, and an addi-
tional 4–5 cm of tissue in both the cranial and caudal directions.
The prescribed dose to the PTV was 78 Gy in 2 Gy fractions, requir-
ing at least 99% of the volume to receive 95% of the prescribed dose
within the 5% to +7% ICRU uniformity criteria [22]. The same
dosimetric constraints were used for both IMRT  IRS and
IMRT + IRS treatment planning, based on the relevant maximum
tolerance doses (indicated as Dmax) and the maximum allowed
relative volumes to be exposed to a certain dose level (indicated
as VxxGy), as published by the Radiation Therapy Oncology Group
(RTOG) for rectum and bladder [23]: V50Gy(rectum) 6 50%,
V70Gy(rectum) 6 20%, Dmax(rectum) 6 76 Gy, V55Gy(bladder) 6 50%,
and V70Gy(bladder) 6 30%. The mean anorectal dose (MARD), mean
anal dose (MAD), and mean rectal dose (MRD) were evaluated for
statistical analysis.Multifactorial nomograms for NTCP prediction
Validated nomograms based on clinical risk factors (use of anti-
coagulants, hormonal therapy, or anti-hypertensives; pelvic node
irradiation; presence of diabetes or haemorrhoids; and a history
of pre-RT abdominal surgery) and dosimetric parameters of the
anorectum (V40Gy and V75Gy) were used to predict for each individ-
ual patient the normal tissue complication probability (NTCP) for
G2–3 acute GI toxicity, G2–3 late rectal bleeding (LRB), G3 LRB,
and G2–3 faecal incontinence (FI) for both the IMRT  IRS and
IMRT + IRS treatment plans [16,17].Identification of beneficent scenarios
To identify scenarios of clinical risk factors predicting a signifi-
cant reduction in GI toxicity scores for a sufficiently large propor-
tion of patients, we first considered the most favourable and the
most unfavourable scenarios, being defined as the binary permuta-
tion of clinical risk factors producing the most positive and the
most negative predicted NTCPs, respectively. From the regression
coefficients of the nomograms it appeared that ‘use of anticoagu-
lants’ and ‘hormonal therapy’ positively affected the predicted
NTCPs. On the other hand ‘presence of diabetes’, ‘presence of
haemorrhoids’, ‘pelvic node irradiation’, and ‘previous abdominal
surgery’ negatively affected the predicted NTCPs. Consequently,
the most unfavourable scenario represents the combination of
‘presence of diabetes’, ‘presence of haemorrhoids’, ‘pelvic node
irradiation’, and ‘previous abdominal surgery’ in absence of ‘use
of anticoagulants’ and ‘hormonal therapy’. The most favourable
scenario represents the combination of ‘use of anticoagulants’
and ‘hormonal therapy’ in absence of ‘presence of diabetes’, ‘pres-
ence of haemorrhoids’, ‘pelvic node irradiation’, and ‘previous
abdominal surgery’. To assess the decrease in predicted NTCPs
between IMRT + IRS and IMRT  IRS for both scenarios, the corre-
sponding permutations of risk factors were applied to all individual
patients in the cohort, while leaving the variation in dosimetric risk
factors unchanged. From the resulting distribution of predicted
changes in NTCPs, the proportion having an NTCP reduction of at
least 5% and 10% points was assessed for both scenarios. Further-
more, we considered all possible scenarios by generating the
remaining binary permutations of clinical risk factors (in total:
32 for G2–3 acute toxicity, 64 for G2–3 LRB, Gr3 LRB, and G2–3
FI) to identify the set of scenarios yielding a predicted NTCP reduc-
tion of at least 5% points in at least 25% of the patients. Finally, a
Boolean expression2 for this set of scenarios was generated to estab-
lish a decision rule per toxicity end-point.2 Propositional formula constructed from simple binary propositions using con-
nectives such as NOT, AND, OR.Statistical analysis
The statistical analyses were performed using the Statistics and
Machine Learning ToolboxTM from MATLAB-software (Version 10.0,
MathWorks, Inc., Natick, MA). The Wilcoxon’s signed rank test was
applied to test for a significant decrease in predicted toxicity rates
between IMRT + IRS and IMRT  IRS. All statistical tests were one-
sided, with p < 0.05 considered to be statistically significant.Results
Dosimetric plan performance with and without IRS
The median implanted IRS volume was 10.6 cc [range: 8.3–
20.4 cc]. No statistically significant difference was observed
between the prostate (CTV) and the PTV volumes in IMRT + IRS
and IMRT  IRS (p = 0.269 and p = 0.603, respectively). The median
anorectum V40Gy was reduced from 53.4% for IMRT  IRS to 47.6%
for IMRT + IRS (p = 0.0357). The median V75Gy was significantly
reduced from 3.9% for IMRT  IRS to 0.4% for IMRT + IRS
(p < 0.0001). The median MARD for IMRT  IRS and IMRT + IRS
was 38.7 Gy and 34.9 Gy, respectively, yielding a significant reduc-
tion (p < 0.001). A significant reduction in the median MAD from
34.3 Gy for IMRT  IRS to 24.8 Gy for IMRT + IRS (p < 0.001) was
observed. The median MRD was significantly reduced from
39.0 Gy for IMRT  IRS to 35.5 Gy for IMRT + IRS (p = 0.009).Predicted NTCP reduction
First, NTCP estimates were calculated for IMRT + IRS and
IMRT  IRS based on the clinical risk factors as given for the indi-
vidual patients. The pair-wise comparison of predicted NTCPs
revealed significantly lower predicted G2–3 acute and late rectal
toxicity rates for IMRT + IRS than for IMRT  IRS; the decrease
was not significant for FI (Table 2). For G2–3 acute toxicity and
for G3 LRB, a decrease in predicted toxicity for both endpoints
was present in 17/26 (65%) patients. For G2–3 LRB, a decrease in
predicted NTCP was expected in 20/26 (77%) patients. For 23/26
patients (88%) no decrease in G2–3 FI was revealed.
In Table 3, the statistics of the predicted NTCPs for both the
most unfavourable and most favourable scenarios are presented.
For the most unfavourable scenario, the G2–3 acute toxicity rate
decreased in 17/26 (65%) patients. For G2–3 LRB, G3 LRB, and
G2–3 FI a decrease in predicted toxicity was present in 22/26
(85%) patients, 21/26 (81%) patients, and in 13/26 (50%) patients,
respectively. For the most favourable scenario, the G2–3 acute tox-
icity rate decreased in 17/26 (65%) patients. For G2–3 LRB, G3 LRB,
and G2–3 FI a decrease in predicted toxicity was present in 17/26
(65%) patients, 13/26 (50%) patients, and in 1/26 (4%) patients,
respectively.Decision rules
Regarding G2–3 acute toxicity, in 22/32 (69%) scenarios an
NTCP-decrease of at least 5% points was predicted to occur in at
least 25% of the patients (Table S1, Supplementary Data). The Boo-
lean decision rule that describes these 22 scenarios was found to
be:
NOT ðA OR EÞ OR ðC AND DÞ OR ðA XOR EÞ AND ðC XOR DÞ
where A = use of anticoagulants; B = diabetes; C = presence of
haemorrhoids; D = pelvic node irradiation; E = hormonal therapy,
F = previous abdominal surgery.
Among these 22 scenarios, the most unfavourable scenario and
5/31 additional scenarios had a median NTCP-reduction of at least
5%.
Table 2
Median [range] predicted acute and late toxicity rates in the entire cohort (N = 26).
NTCPIMRT+IRS (%) NTCPIMRTIRS (%) DNTCP (%) p value
Nomacu 20 [8–33] 22 [11–32] 3 [3 to 15] <0.001
3 yr G2–3 LRB 5 [4–11] 6 [4–13] 1 [1 to 5] <0.0001
3 yr G3 LRB 3 [3–10] 4 [4–11] 1 [1 to 2] <0.002
G2–3 LFI 1 [0–5] 2 [0–6] 1n.s. [0–2] 0.006n.s.
Abbreviations: Nomacu = acute RTOG Grade 2 to Grade 3 lower gastro-intestinal toxicity; 3 yr G2–3 LRB = 3 years of Grade 2 to Grade 3 late rectal bleeding; 3 yr G3
LRB = 3 years of Grade 3 late rectal bleeding; G2–3 LFI = chronic Grade 2 to Grade 3 late faecal incontinence; IRS = implantable rectum spacer. n.s.Not significant.
Table 3
Median [range] predicted acute and late toxicity rates stratified by scenario.
Scenario NTCPIMRT+IRS (%) NTCPIMRTIRS (%) DNTCP (%) p value DNTCPP 5% (%) DNTCPP 10% (%)
Nomacu MU 45 [33–54] 48 [39–59] 5 [4 to 20] <0.001 50 12
MF 10 [6–14] 11 [8–16] 2 [2 to 8] <0.001 4 0
3yr G2–3 LRB MU 17 [13–21] 22 [15–30] 5 [4 to 16] <0.0001 50 12
MF 4 [3–4] 5 [4–6] 1 [1 to 3] <0.0001 0 0
3yr G3 LRB MU 13 [11–16] 17 [12–22] 3 [2 to 10] <0.0001 19 0
MF 3 [2–3] 3 [3–4] 1 [0–2] 0.02 0 0
G2–3 LFI MU 12 [7–17] 13 [9–19] 1 [3 to 12] 0.03 12 4
MF 0 [0–1] 1 [0–1] 0 [0–1] 0.06n.s. 0 0
Abbreviations: MU = most unfavourable scenario; MF = most favourable scenario; NTCPIMRT+IRS = normal-tissue complication probability for IMRT plans with IRS gel;
NTCPIMRTIRS = normal-tissue complication probability for IMRT plans without IRS gel; DNTCPP x% = percentage of patients in study cohort having an NTCP decrease of at
least x% points; IRS = implantable rectal spacer; Nomacu = acute RTOG Grade 2 to Grade 3 lower gastro-intestinal toxicity; 3 yr G2–3 LRB = 3 years of Grade 2 to Grade 3 late
rectal bleeding; 3 yr G3 LRB = 3 years of Grade 3 late rectal bleeding; G2–3 LFI = chronic Grade 2 to Grade 3 late faecal incontinence; IRS = implantable rectum spacer. n.s.Not
significant.
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least 5% points was predicted to occur in at least 25% of the
patients (Table S2, Supplementary Data). The Boolean decision rule
that describes these 12 scenarios was found to be:
F AND ðNOT ðAÞ AND ððB OR CÞ AND ðD AND EÞ OR NOT
ðD OR EÞÞÞ OR ðNOT ðCÞ AND D AND NOT ðEÞÞ OR
ðC AND D AND NOT ðEÞÞ
where A = use of anticoagulants; B = diabetes; C = presence of
haemorrhoids; D = pelvic node irradiation; E = hormonal therapy,
F = previous abdominal surgery.
For G3 LRB and G2–3 FI an NTCP-decrease of at least 5% points
was not predicted to occur in at least 25% of the patients.
Discussion
This is the first study to assess the benefits of an IRS for reduc-
ing GI toxicity in prostate cancer patients scheduled for IMRT prior
to implantation of such a device. We identified combinations of
clinical risk factors for which IRS implantation is predicted to be
beneficial. For two clinically relevant toxicity end-points, we gen-
erated decision rules to identify patients who are expected to ben-
efit most from the implantation of an IRS, based solely on their
clinical risk profiles and not on dosimetric or genetic factors. The
probability of developing GI toxicity is not only related to the dose
and the volume of the anorectum receiving a high radiation dose,
but also depends on clinical risk factors and genetic profiles. GI
toxicity is a concern in EBRT of prostate cancer and its adverse
effect on the quality of life cannot be ignored. Dose-escalated IMRT
up to a dose of 78 Gy has raised the rates of acute and chronic
GradeP 2 rectal toxicity compared with lower doses (e.g., 68 Gy)
from 3% to 20% and 5% to 21%, respectively [24–28]. Keeping the
volume fraction of the anorectum receiving more than 75 Gy
(V75Gy) below 5% has been demonstrated to be predictive of late
rectal bleeding [29]. Therefore, it is important to use techniques
that prevent rectal volumes from being exposed to high doses.
Implantation of an absorbable IRS between the prostate and the
anterior rectal wall artificially increases the distance between theprostate and the anterior rectal wall, and hence reduces the dose
delivered to the anorectum [30,31]. Besides dosimetric factors, sev-
eral clinical risk factors have been shown to predict for radiation-
induced GI toxicity in prostate cancer patients. Based on combina-
tions of scenarios of clinical risk factors, we developed the first set
of decision rules to predict the estimated toxicity reduction of an
IRS prior to implantation. This introduces the opportunity to better
select patients for IRS implantation, avoid unbeneficial implanta-
tions and possible complications, enhance quality of life, and con-
sequently improve the cost-effectiveness of the treatment. In
addition to dosimetric and clinical factors, the prediction could
possibly be further improved by including genetic biomarkers to
select those patients having increased risk factors for increased
rectal toxicity [32–34]. Recently the first replicated genetic associ-
ations were reported for adverse reactions to EBRT [35]. A next step
could therefore be to incorporate genetic risk in those models [34].
The multifactorial nomograms by Valdagni et al. were used in
our study to predict acute and late toxicity rates [16,17]. In our
patient group, these nomograms revealed a significant decrease
in G2–3 acute and late GI toxicity. When we compared the most
unfavourable with the most favourable scenario, a most unfavour-
able scenario was predicted to be beneficial with IMRT + IRS, while
the benefit in the most favourable scenario was minimal. Between
those two extreme scenarios, multiple other scenarios were identi-
fied yielding a predicted NTCP reduction of at least 5% points in at
least 25% of patients. To select patients for IRS implantation, the
concept of late rectal toxicity as a consequential late effect arising
from acute RT injury is important [36]. This implies that the deci-
sion rule we developed to predict a clinically relevant reduction of
acute toxicity in a sufficiently large proportion of patients after
implantation of an IRS, could be used to select optimal candidates
for implantation of an IRS, and hence reduce acute and conse-
quently late toxicities. Regarding G2–3 acute toxicity, in 22 scenar-
ios an NTCP-decrease of at least 5% points was predicted to occur in
at least 25% of the patients (Table S1). The interpretation of the cor-
responding decision rule covering these scenarios is as follows:
first, the conjunction of absence of ‘use of anticoagulants’ and
absence of ‘hormonal therapy’ represents 8 scenarios that corre-
spond to the Boolean expression NOT (A OR E) (Table S1). Secondly,
122 Patient selection for spacer implantation6 additional scenarios are provided by the conjunction of both
‘presence of haemorrhoids’ and ‘pelvic node irradiation’. This cor-
responds to the Boolean expression (C AND D). The remaining 8
scenarios are described by the presence of either ‘use of anticoag-
ulants’ or ‘hormonal therapy’, in conjunction with either ‘presence
of haemorrhoids’ or ‘pelvic node irradiation’. This corresponds to (A
XOR E) AND (C XOR D). These 3 expressions are combined in a dis-
junctive way to establish the full decision rule. From this decision
rule, it follows that diabetes status has no impact on the decision
rule. For G2–3 LRB, in 12 scenarios an NTCP-decrease of at least
5% points was predicted to occur in at least 25% of the patients.
From the corresponding rule, it follows that in absence of pre-RT
abdominal surgery, the implantation of an IRS is predicted to show
no clinically relevant benefit for G2–3 LRB.
The present study has several limitations. First, the confidence
intervals of the regression coefficients in the logistic regression
model of the nomograms were not incorporated in our analysis.
Hence, confidence intervals for the predicted NTCPs have not been
computed, possibly leading to an over- or underestimation. Fur-
thermore, the nomograms used were gathered from clinical data
acquired between 2002 and 2004, an era of less conformal dose
delivery techniques compared to modern IMRT. Nowadays, IMRT
with daily image-guided set-up correction enables accurate dose
delivery, thus possibly enhancing the non-dosimetric predictors
of rectal toxicity. Moreover, the two decision rules we developed
are based on different clinical risk factors, and not on dosimetric
factors. Further, the nomograms used are only internally validated,
and stand in need of external clinical prospective validation. Next,
as far as the predictive performance of the decision rules is con-
cerned, their sensitivity, specificity, and calibration have to be
assessed in an independent test-population. Finally, other predic-
tion models exist with other clinical factors that might influence
acute and late GI toxicity [37,38]. Hamstra et al. reported that
patient age, a history of myocardial infarction, and congestive
heart failure are predictors for G3 GI toxicity [37]. However, they
concluded that the use of anticoagulants increased toxicity inde-
pendent of age and comorbidity. The use of anticoagulants is
already included in the nomograms of Valdagni et al. Tucker
et al. also reported that patients with cardiovascular disease had
a significantly higher incidence of late rectal toxicity [38]. Those
risk factors have not been included in the nomogram of Valdagni
et al. This is therefore a limitation of their prediction model.
In the present study, we evaluated differences in predicted
NTCP due to the implantation of an absorbable hydrogel spacer.
We investigated combinations of clinical risk factors to generate
decision rules in order to predict clinical scenarios in which
patients are expected to benefit most from spacer implantation.
Wolf et al. recently published a study comparing the dosimetric
differences between various spacing methods, showing that bal-
loon spacers had a more pronounced effects than hydrogel spacers
[39]. At the time of planning, balloon spacers revealed a 63% reduc-
tion of the rectum surface encompassed by the 95% isodose-line, in
comparison to 38% for the hydrogel. However, they were unable to
demonstrate any clinically relevant difference in acute GI toxicity.
The relevant scenarios of clinical risk factors that were identified in
our study are based on treatment plans with and without an
implanted hydrogel. Our method could also be applied to patients
with an implanted balloon spacer. According to the nomograms,
balloon spacers would probably not decrease acute toxicity more
than hydrogel spacers, because of similar mean rectal dose. How-
ever late toxicity is expected to decrease with balloon spacers
due to a lower V75Gy in comparison to hydrogel spacers. Further
research is needed to test this hypothesis.
The results presented in this paper are also valuable for policy
making by health care insurance companies. Currently, there is
no reimbursement for IRS implantation in the Netherlands. Onlynew treatment modalities with level I–II scientific evidence are
approved for reimbursement. A reliable patient-selection tool
may fundamentally change this procedure. A model-based
approach could possibly be instrumental for this, since such an
approach was also employed for the introduction of proton therapy
in the Netherlands. According to guidelines of the Dutch National
Society of Radiotherapy Oncology, a predicted reduction of 10%
of grade 2, 5% of grade 3 and 2% of grade 4–5 complications would
be required to justify the increased costs for such treatment [40]. If
we apply these thresholds, we estimate that approximately 20% of
the localized prostate cancer patients would benefit from an IRS,
and consequently should have its placement reimbursed. If the
IRS is combined with brachytherapy, proton therapy, or stereotac-
tic radiotherapy, the toxicity reduction may even be more pro-
nounced due to the steep dose gradients of these techniques.
However, this hypothesis needs to be clinically validated.
The next step will be to implement the cost-effectiveness model
to obtain a four-level decision support system with complete inte-
gration of dose, toxicity, cost-effectiveness, and genetic input
[41,42].
In conclusion, the implantation of an IRS is predicted to reduce
the G2–3 acute and late rectal toxicity rates in prostate cancer
patients undergoing IMRT. Scenarios of clinical risk factors were
identified for which implantation of an IRS is predicted to signifi-
cantly reduce G2–3 acute and late rectal toxicity rates with IMRT
prior to implantation of the IRS. Decision rules were developed
to support the physician in selecting those patients who will ben-
efit most from IRS implantation prior to IMRT planning. A prospec-
tive follow-up study in an independent patient cohort is needed to
assess the predictive performance of the decision rules.
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